000028 深市 国药一致

证券代码：000028、200028                证券简称：国药一致、一致Ｂ                      公告编号：2020-34
 国药集团一致药业股份有限公司 2020 年第三季度报告正文

                      第一节 重要提示

    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人林兆雄、主管会计工作负责人谷国林及会计机构负责人(会计主管人员)王颖声明：保证季度报告中财务报表的真实、准确、完整。


                    第二节 公司基本情况

一、主要会计数据和财务指标
公司是否需追溯调整或重述以前年度会计数据
√ 是 □ 否
追溯调整或重述原因
同一控制下企业合并

                                                                上年度末              本报告期末比上年度
                                  本报告期末                                                末增减

                                                      调整前            调整后            调整后

 总资产（元）                    42,013,200,732.51    33,520,609,123.67    34,028,843,214.20            23.46%

 归属于上市公司股东的净资产

 （元）                          13,554,151,733.76    12,806,410,865.92    12,911,140,435.88            4.98%

                                                          本报告期                              年初至报
                                            上年同期      比上年同                上年同期      告期末比
                              本报告期                              年初至报                    上年同期
                                                            期增减  告期末                      增减

                                        调整前  调整后  调整后            调整前  调整后  调整后

 营业收入（元）              15,710,564 13,647,793 13,824,236          42,880,505 38,875,940 39,423,43

                                                            13.65%                                8.77%
                                ,937.11  ,431.64  ,956.99            ,125.63  ,809.07  5,772.29

 归属于上市公司股东的净利润  354,134,16 311,310,70 310,253,59          997,585,74 962,144,06 959,408,0

 （元）                                                      14.14%                                3.98%
                                  5.83      6.52      2.48              6.42      6.92    07.03

 归属于上市公司股东的扣除非经 354,311,45 303,365,28 303,365,28          981,328,47 943,065,72 943,065,7

 常性损益的净利润（元）                                      16.79%                                4.06%
                                  3.14      0.52      0.52              2.59      8.47    28.47

 经营活动产生的现金流量净额  545,143,14 -90,795,42 -80,360,84          1,983,347, 1,072,962, 1,058,793,

 （元）                                                      778.37%                                87.32%
                                  2.89      0.13      0.58            186. 24    161.22  280. 31

 基本每股收益（元/股）              0.83      0.74      0.72  15.28%      2.33      2.25    2.24    4.02%

 稀释每股收益（元/股）              0.83      0.74      0.72  15.28%      2.33      2.25    2.24    4.02%

 加权平均净资产收益率                                      上升 0.15                              下降 0.29
                                2.65%    2.53%    2.50% 个百分点    7.56%    7.94%    7.85% 个百分点

非经常性损益项目和金额
√ 适用 □ 不适用

                                                                                                  单位：元

                        项目                          年初至报告期期末金额              说明

 非流动资产处置损益（包括已计提资产减值准备的冲销部分）            6,670,438.32 主要为门店退租收益。


 计入当期损益的政府补助（与企业业务密切相关，按照国家统                        主要为受新冠肺炎疫情影响，本
 一标准定额或定量享受的政府补助除外）                              36,307,932.91 期收到的各类专项补助、税收减
                                                                              免等。

 单独进行减值测试的应收款项、合同资产减值准备转回                    378,494.91

 受托经营取得的托管费收入                                            961,488.75

 除上述各项之外的其他营业外收入和支出                            -11,989,346.42

 其他符合非经常性损益定义的损益项目                                  955,958.26

 减：所得税影响额                                                  7,360,561.86

    少数股东权益影响额（税后）                                    9,667,131.04

 合计                                                              16,257,273.83            --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目，以及把《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益项目界定为经常性损益的项目的情形。
二、报告期末股东总数及前十名股东持股情况表
1、普通股股东和表决权恢复的优先股股东总数及前 10名股东持股情况表

                                                                                                  单位：股

 报告期末普通股股东总数                                报告期末表决权恢复的优先

                                                34,927 股股东总数（如有）                              0

                                          前 10 名股东持股情况

                                                            持有有限售条件        质押或冻结情况

  股东名称      股东性质      持股比例      持股数量      的股份数量

                                                                              股份状态        数量

 国药控股股份有 国有法人

 限公司                                56.06%    239,999,991      5,505,770

 FIRST SENTIER
 INVESTORS
 GLOBAL

 UMBRELLA    境外法人

 FUND PLC -                            2.68%      11,469,644

 FSSA CHINA
 GROWTH
 FUND
 上海高毅资产管

 理合伙企业（有 境内非国有法人          2.34%      10,000,0